Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 25;3(1):vdab118.
doi: 10.1093/noajnl/vdab118. eCollection 2021 Jan-Dec.

Avelumab in newly diagnosed glioblastoma

Francois H Jacques  1 , Garth Nicholas  2   3 , Ian A J Lorimer  2   4   3 , Victorine Sikati Foko  1 , Jasmine Prevost  1 , Nathalie Dumais  1 , Katy Milne  5 , Brad H Nelson  5   6   7 , John Woulfe  8 , Gerard Jansen  8 , B Erik Apedaile  1
Affiliations

Avelumab in newly diagnosed glioblastoma

Francois H Jacques et al. Neurooncol Adv. .

Abstract

Background: Glioblastoma (GBM) is known to use both local and systemic immunosuppressive strategies. One such strategy is the expression of the immune checkpoint protein programmed cell death ligand-1 (PD-L1) by both tumor cells and tumor-associated immune cells. Recent phase III trials using IgG4 antibodies targeting PD-1, the ligand for PD-L1, failed to show any benefit. Avelumab is an IgG1 monoclonal antibody targeting PD-L1. In contrast to the previously tested immune checkpoint inhibitors, it can directly bind tumor cells and immune cells expressing PD-L1 and can induce antibody-dependent cellular cytotoxicity.

Methods: We conducted a single center, open label, phase II study where avelumab 10 mg/kg IV Q2W was added concurrently to the first monthly temozolomide cycle in patients with newly diagnosed GBM. Immunohistochemical analyses were performed on surgery samples. The primary objective was safety. Secondary objectives were efficacy outcomes according to the immunotherapy Response Assessment in Neuro Oncology criteria, progression free survival (PFS), and overall survival (OS). Exploratory objectives aimed at determining prognostic biomarkers.

Results: Thirty patients were started on therapy and two were lost to follow-up. Median follow-up time (reverse Kaplan-Meier) was 41.7 months (IQR: 28.3-43.4). Three (10.0%) patients had a related or possibly related treatment emergent adverse event that lead to transient or permanent discontinuation of avelumab. Eight (26.7%) patients had one or more immune-related adverse events, and 8 (26.7%) patients had an infusion-related reaction. The overall response rate was 23.3%, median PFS was 9.7 months, and the median OS was 15.3 months. No pretreatment biomarkers showed any predictive value.

Conclusions: The addition of avelumab to standard therapy in patients with GBM was not associated with any new safety signal. There was no apparent improvement in OS.

Trial registration: NCT03047473 Registered February 9, 2017.

Keywords: PD-L1; avelumab; glioblastoma; immune checkpoint inhibitor; phase II.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan Meier plots for patients grouped according to steroid use. A. progression-free survival in patients who did not require the use of steroids at month 1 (red) and those who did (blue). B. Overall survival in patients who did not require the use of steroids at month 1 (red) and those who did (blue).
Figure 2.
Figure 2.
Biomarker analyses: A. Multicolour immunohistochemistry analyses of first surgery samples from trial patients. Top row of bar graphs show the results for the CD3/CD8/CD20 analysis. The bottom row of bar graphs show results for PD1/PDL1/CD68 analysis. Y axes show the number of positive cells per mm2 and x axes show results for individual patients. B. Single cell RNA-seq expression data from twenty-eight glioblastoma patients sequenced by Neftel et al. were analyzed for mRNA expression of immunohistochemistry markers used in this study, using Broad Institute Single Cell portal software https://singlecell.broadinstitute.org/single_cell. C. Comparison of immune status in first and second surgery samples from trial patients. Y axes show the number of positive cells per mm2 and x axes show paired bars for individual patient samples from first (grey bar) and second surgeries (black bar).
See this image and copyright information in PMC

References

    1. Stupp R, Mason WP, van den Bent MJ, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed
    1. Preusser M, de Ribaupierre S, Wöhrer A, et al. . Current concepts and management of glioblastoma. Ann Neurol. 2011;70(1):9–21. - PubMed
    1. Central Brain Tumor Registry of the United States. http://www.cbtrus.org/. Accessed December 8, 2020.
    1. Malmström A, Grønberg BH, Marosi C, et al. ; Nordic Clinical Brain Tumour Study Group (NCBTSG) . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–926. - PubMed
    1. Hegi ME, Diserens AC, Godard S, et al. . Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10(6):1871–1874. - PubMed

Associated data